Diabetes Market Research
Diabetes mellitus is a chronic metabolic disorder that is caused due to a failure of the body to produce the hormone insulin and/or an inability of the body to respond adequately to circulating insulin.
Research indicates that the global diabetes market was worth $27.3bn in 2008 and was led by insulin analogs which captured 45.0% of the market followed by glitazones that captured a share of 22.8%. It has been observed that US is the largest diabetes market globally.
The Diabetes market research report provides insight into the pipeline status of diabetes drugs by company and by stage, as well as a summary of the latest news and developments in this area. In addition to new developments and disease specific pipeline projects, the listed reports also contain extensive information in tabular format on a company’s full product pipeline, and products by phase of development with regard to the therapy area. The study also helps in keeping track of the industry-specific competitors and partners by better understanding their product pipeline.
The study basically aims at providing a comprehensive overview of the on-goings of the diabetes drug therapy market.